Moderna and Uber say they will work together initially to provide accessible, credible information on vaccine safety through Uber's in-app messaging.
The two companies will also work with public health and other organizations to identify additional opportunities to support ongoing efforts to broaden access to COVID-19 vaccines.
Additional options being evaluated include incorporating ride scheduling directly into the immunization appointment process, and possibly integrating with vaccine providers' systems to text reminders and enable patients to book rides in advance of their first or second immunization appointments.
In December, Uber committed 10 m free or discounted rides to help ensure transportation is not a barrier to getting a vaccine.
Targeting communities hardest hit by the pandemic, Uber partnered with the National Urban League, National Action Network and the Morehouse School of Medicine.
Uber will continue to build a broad coalition of organizations committed to breaking down transportation barriers in these communities.
The Moderna COVID-19 Vaccine has been authorized for emergency use in the US by the FDA for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older and has been authorized by Health Canada for the immunization of Canadians 18 years of age and older under an Interim Order.
The Moderna COVID-19 Vaccine has also been granted a Conditional Marketing Authorization by the European Commission, based upon the recommendation of the European Medicines Agency, which authorizes the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.
While initially targeting Uber users in the United States, the companies anticipate expanding this partnership globally in the coming months alongside ongoing immunization efforts.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial